APRE
Aprea Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$0.76
+1.32%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$0.78
From 52W high−53.95%
Volume79924.00
Market cap$9.57M
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataSep 18, 2026
Open
$0.78
From 52W high
−53.95%
Volume
79924.00
Market cap
$9.57M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
2.6x
P/E (TTM)
—
RSI (14)
48.1
MomentumView details →
1D Return
+1.32%
YTD Return
−12.06%
SummaryUpdated Jun 1, 2026
Aprea Therapeutics, Inc. (NASDAQ:APRE) is a clinical-stage biopharmaceutical company founded in 2002 and based in Boston, Massachusetts. The company went public in October 2019 and focuses on developing novel cancer therapeutics that target DNA damage response pathways. Aprea operates as a small biotechnology firm dedicated to advancing innovative treatments for patients with advanced solid tumors through its pipeline of experimental drugs currently in various stages of clinical development.
Similar companies
Latest newsMore news →